Natera (NASDAQ:NTRA) CFO Sells $101,456.18 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 482 shares of the business’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $210.49, for a total transaction of $101,456.18. Following the completion of the transaction, the chief financial officer owned 57,496 shares in the company, valued at $12,102,333.04. The trade was a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Burkes Brophy also recently made the following trade(s):

• On Friday, May 1st, Michael Burkes Brophy sold 313 shares of Natera stock. The shares were sold at an average price of $206.16, for a total transaction of $64,528.08.
• On Wednesday, April 29th, Michael Burkes Brophy sold 3,070 shares of Natera stock. The shares were sold at an average price of $193.74, for a total transaction of $594,781.80.
• On Monday, April 27th, Michael Burkes Brophy sold 1,993 shares of Natera stock. The shares were sold at an average price of $204.14, for a total transaction of $406,851.02.
• On Tuesday, March 10th, Michael Burkes Brophy sold 785 shares of Natera stock. The shares were sold at an average price of $204.13, for a total transaction of $160,242.05.

Natera Price Performance

NASDAQ:NTRA opened at $219.82 on Friday. The firm has a market capitalization of $31.28 billion, a price-to-earnings ratio of -143.67 and a beta of 1.57. The company’s 50-day moving average is $202.23 and its two-hundred day moving average is $215.02. Natera, Inc. has a 1-year low of $131.81 and a 1-year high of $256.36.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, May 7th. The medical research company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.07). Natera had a negative return on equity of 15.28% and a negative net margin of 9.03%.The company had revenue of $696.64 million during the quarter, compared to analyst estimates of $617.10 million. During the same quarter in the prior year, the company posted ($0.50) earnings per share. The business’s revenue was up 38.8% compared to the same quarter last year. As a group, equities analysts anticipate that Natera, Inc. will post -1.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Natera

Large investors have recently added to or reduced their stakes in the business. Reflection Asset Management purchased a new stake in Natera during the 4th quarter worth approximately $29,000. Palladiem LLC purchased a new stake in Natera during the 4th quarter worth approximately $31,000. Horizon Investments LLC purchased a new stake in Natera during the 3rd quarter worth approximately $32,000. International Assets Investment Management LLC increased its stake in Natera by 132.9% during the 1st quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after buying an additional 97 shares during the period. Finally, Bank of Jackson Hole Trust increased its stake in Natera by 103.8% during the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after buying an additional 83 shares during the period. 99.90% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

NTRA has been the topic of several recent analyst reports. Wells Fargo & Company upped their price objective on shares of Natera from $205.00 to $215.00 and gave the stock an “equal weight” rating in a report on Friday, February 27th. Canaccord Genuity Group restated a “buy” rating on shares of Natera in a report on Monday, January 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a report on Tuesday, April 21st. William Blair initiated coverage on shares of Natera in a report on Tuesday, April 14th. They issued an “outperform” rating on the stock. Finally, Wall Street Zen upgraded shares of Natera from a “hold” rating to a “buy” rating in a report on Saturday, April 18th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $253.47.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.